PASSAGE BIO, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $23.3M | $40.2M | $61.4M | — | — | — | — |
| SG&A Expense | — | $19.9M | $25.0M | $41.6M | $49.3M | $60.1M | $30.1M | $7.0M |
| Operating Income | — | $-49.3M | $-70.4M | $-108.4M | $-138.4M | $-185.7M | $-112.9M | $-37.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — | — | — | — | — |
| Net Income | — | $-45.5M | $-64.8M | $-102.1M | $-136.1M | $-185.4M | $-112.2M | $-45.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 | $-2.91 | $-10.77 |
| EPS (Diluted) | — | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 | $-2.91 | $-10.77 |
| Shares Outstanding (Basic) | 3.2M | 3.2M | 3.1M | 54.7M | 54.4M | 53.3M | 38.6M | 4.3M |
| Shares Outstanding (Diluted) | 3.2M | 3.2M | 3.1M | 54.7M | 54.4M | 53.3M | 38.6M | 4.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |